Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037676 | 0.81 | ELANE (0.31) | ELANECYP1A2CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL11670613 | 0.78 | KDM4E (0.33) | — | |
| SCHEMBL11671275 | 0.78 | KDM4E (0.31) | — | |
| SCHEMBL11670927 | 0.76 | KDM4E (0.54) | MAPTKMT2ACYP1A2 | |
| SCHEMBL6321020 | 0.76 | HTT (0.35) | MAPTCYP2C19 | |
| SCHEMBL11671025 | 0.73 | MAPK1 (0.48) | MAPTKMT2ACYP1A2CYP2C19 | |
| SCHEMBL7289270 | 0.72 | ESR1 (0.44) | CYP1A2CYP2C19 | |
| SCHEMBL12147796 | 0.71 | ELANE (0.37) | KMT2AELANEHPGDSCYP1A2CYP2E1 | |
| SCHEMBL24844527 | 0.71 | MAPT (0.39) | MAPTKMT2ACYP1A2CYP2C19 | |
| SCHEMBL6625298 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101151244-B | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI | 2014-09-03 | — | — | CN | disclosed |
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| CN-101151244-A | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2008-03-26 | — | — | CN | disclosed |
| EP-1868991-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006107661-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| US-4036965-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | MAPT 695/4885KMT2A 123/4885ELANE 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.